Rethinking the role of oncogenes in papillary thyroid cancer initiation

Frontiers in Endocrinology

Volumn 3, Issue JUN, 2012, Pages

  Vitale, Mario ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874439754     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00083     Document Type: Article

References (35)

1. Bounacer, A., Wicker, R., Caillou, B., Cailleux, A. F., Sarasin, A., Schlumberger, M., and Suarez, H. G. (1997). High prevalence of activating ret proto-onco-gene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 15, 1263-1273.
2. Brummer, T., Martin, P., Herzog, S., Misawa, Y., Daly, R. J., and Reth, M. (2006). Functional analysis of the regulatory requirements of B-Raf and the B-Raf (V600E) oncoprotein. Oncogene 25, 6262-6276.
3. Charles, R. P., Iezza, G., Amendola, E., Dankort, D., and McMahon, M. (2011). Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res. 71, 3863-3871.
4. Cinti, R., Yin, L., Ilc, K., Berger, N., Basolo, F., Cuccato, S., Giannini, R., Torre, G., Miccoli, P., Amati, P., Romeo, G., and Corvi, R. (2000). RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH. Cytogenet. Cell Genet. 88, 56-61.
5. Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., Sherman, S. I., Steward, D. L., and Tuttle, R. M. (2009). Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167-1214.
6. Corvi, R., Martinez-Alfaro, M., Harach, H. R., Zini, M., Papotti, M., and Romeo, G. (2001). Frequent RET rearrangements in thyroid papillary microcarcinoma detected by interphase fluorescence in situ hybridization. Lab. Invest. 81, 1639-1645.
7. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Mai tl and, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Mar ais, R., Marshall, C. J., Wooster, R., Str atton, M. R., and Futreal, P. A. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
8. Davies, L., and Welch, H. G. (2006). Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295, 2164-2167.
9. Fusco, A., Grieco, M., Santoro, M., Berlingieri, M. T., Pilotti, S., Pierotti, M. A., Della Porta, G., and Vecchio, G. (1987). A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 328, 170-172.
10. Guerra, A., Sapio, M. R., Marotta, V., Campanile, E., Rossi, S., Forno, I., Fugazzola, L., Budillon, A., Moccia, T., Fenzi, G., and Vitale, M. (2012a). The primary occurrence of BRAFV600E is a rare clonal event in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 97, 517-524.
11. Guerra, A., Fugazzola, L., Marotta, V., Cirillo, M., Rossi, S., Cirello, V., Forno, I., Moccia, T., Budillon, A., and Vitale, M. (2012b). A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J. Clin. Endocrinol. Metab. (in press)
12. Guerra, A., Sapio, M. R., Marotta, V., Campanile, E., Moretti, M. I., Deandrea, M., Motta, M., Limone, P. P., Fenzi, G., Rossi, G., and Vitale, M. (2011). Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr. J. 58, 31-38.
13. Hodgson, N. C., Button, J., and Solorzano, C. C. (2004). Thyroid cancer: is the incidence still increasing? Ann. Surg. Oncol. 11, 1093-1097.
14. Ishizaka, Y., Kobayashi, S., Ushijima, T., Hirohashi, S., Sugimura, T., and Nagao, M. (1991). Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene 6, 1667-1672.
15. Jhiang, S. M., Sagartz, J. E., Tong, Q., Parker-Thornburg, J., Capen, C. C., Cho, J. Y., Xing, S., and Ledent, C. (1996). Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137, 375-378.
16. Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., and Fagin, J. A. (2003). High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454-1457.
17. Knauf, J. A., Ma, X., Smith, E. P., Zhang, L., Mitsutake, N., Liao, X. H., Refetoff, S., Nikiforov, Y. E., and Fagin, J. A. (2005). Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 65, 4238-4245.
18. Marotta, V., Guerra, A., Sapio, M. R., and Vitale, M. (2011a). RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur. I Endocrinol. 165,499-507.
19. Marotta, V., Sapio, M. R., Guerra, A., and Vitale, M. (2011b). BRAF mutation in cytology samples as a diagnostic tool for papillary thyroid carcinoma. Expert Opin. Med. Diagn. 5, 277-290.
20. Moretti, S., De Falco, V., Tamburrino, A., Barbi, F., Tavano, M., Avenia, N., Santeusanio, F., Santoro, M., Macc hi arulo, A., and Puxeddu, E. (2009). Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif. Biochim. Biophys. Acta 1793, 1634-1645.
21. Nikiforov, Y. E. (2002). RET/PTC rearrangement in thyroid tumors. Endocr. Pathol. 13, 3-16.
22. Nikiforov, Y. E. (2006). Radiation-induced thyroid cancer: what we have learned from chernobyl. Endocr. Pathol. 17, 307-317.
23. Nucera, C., Nehs, M. A., Nagarkatti, S. S., Sadow, P. M., Mekel, M., Fischer, A. H., Lin, P. S., Bollag, G. E., Lawler, J., Hodin, R. A., and Parangi, S. (2011). Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclini-cal models of human thyroid cancer. Oncologist 16, 296-309.
24. Pierotti, M. A., Santoro, M., Jenkins, R. B., Sozzi, G., Bongarzone, I., Grieco, M., Monzini, N., Miozzo, M., Herrmann, M. A., and Fusco, A. (1992). Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc. Natl. Acad. Sci. U.S.A. 89, 1616-1620.
25. Salerno, P., De Falco, V., Tamburrino, A., Nappi, T. C., Vecchio, G., Schweppe, R. E., Bollag, G., Santoro, M., and Salvatore, G. (2010). Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 95, 450-455.
26. Santoro, M., Carlomagno, F., Hay, I. D., Herrmann, M. A., Grieco, M., Melillo, R., Pierotti, M. A., Bongarzone, I., Della Porta, G., and Berger, N. (1992). Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J. Clin. Invest. 89, 1517-1522.
27. Santoro, M., Chiappetta, G., Cerrato, A., Salvatore, D., Zhang, L., Manzo, G., Picone, A., Portella, G., Santelli, G., Vecchio, G., and Fusco, A. (1996). Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 12, 1821-1826.
28. Santoro, M., Melillo, R. M., and Fusco, A. (2006). RET/ PTC activation in papillary thyroid carcinoma: European journal of endocrinology prize lecture. Eur. J. Endocrinol. 155, 645-653.
29. Santoro, M., Melillo, R. M., Grieco, M., Berlingieri, M. T., Vecchio, G., and Fusco, A. (1993). The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ. 4, 77-84.
30. Sapio, M. R., Guerra, A., Marotta, V., Campanile, E., Formisano, R., Deandrea, M., Motta, M., Limone, P. P., Fenzi, G., Rossi, G., and Vitale, M. (2011). High growth rate of benign thyroid nodules bearing RET/ PTC rearrangements. J. Clin. Endocrinol. Metab. 96, E916-E919.
31. Unger, K., Zitzelsberger, H., Salvatore, G., Santoro, M., Bogdanova, T., Braselmann, H., Kastner, P., Zurnadzhy, L., Tronko, N., Hutzler, P., and Thomas, G. (2004). Heterogeneity in the distribution of RET/PTC rearrangements within individual post-cherno-byl papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 89, 4272-4279.
32. Wellbrock, C., Karasarides, M., and Marais, R. (2004). The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5, 875-885.
33. Xing, M. (2005). BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12, 245-262.
34. Xing, M. (2007). BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 28, 742-762.
35. Zatelli, M. C., Trasforini, G., Leoni, S., Frigato, G., Bur atto, M., Tagliati, F., Rossi, R., Cavazzini, L., Roti, E., and degli Uberti, E. C. (2009). BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur. J. Endocrinol. 161, 467-473.